

# General Data Protection Regulation (GDPR) related statement from Solani Therapeutics

---

Solani Therapeutics Ltd has reviewed its data collecting, handling and storing practices, and processes regarding data of individuals, with regard to the EU's General Data Protection Regulation coming into effect on the 27th of May 2018. The company has prepared a register analysis and a report for internal use to unify and guide related practices.

The second and the third party data at Solani are limited to collaboration partners (present and potential), subcontractors and other service providers, and to names, titles, office phone numbers, office addresses, and work email addresses of individuals representing these parties. These data have been obtained either by personal first contacts or by participating in so-called partnering events where contact information of participants is available by consent. Solani does not buy any personal data, and does not process or store any personal data beyond one's professional capacity related to scientific and commercial negotiations Solani undertakes with various parties.

Solani does not maintain a customer or a prospect register containing data of individuals. For marketing purposes Solani compiles once a year a register of email addresses from its correspondence with collaboration partners to send out a seasonal greeting using a third party service designed for this. A recipient has the right to cancel the greeting upon receipt, resulting in the address being deleted from the register.

Solani does not part with any unconsented information regarding individuals, except if disclosing the data is required by law. All the service providers Solani uses for data transfer, processing and storing have stated their compliance with the GDPR. All data is password protected.

For any further questions about GDPR, please turn to the company's management.

21.5.2018  
Solani Therapeutics Ltd

SOLANI  
THERAPEUTICS